Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Cabaletta Bio stock price, quote, forecast and news

CABA
US12674W1099
A2PTTB

Price

5.76
Today +/-
-0.19
Today %
-3.58 %
P

Cabaletta Bio stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Cabaletta Bio stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Cabaletta Bio stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Cabaletta Bio stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Cabaletta Bio's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Cabaletta Bio Stock Price History

DateCabaletta Bio Price
8/27/20245.76 undefined
8/26/20245.97 undefined
8/23/20246.06 undefined
8/22/20245.80 undefined
8/21/20245.90 undefined
8/20/20244.89 undefined
8/19/20244.97 undefined
8/16/20244.54 undefined
8/15/20244.46 undefined
8/14/20244.38 undefined
8/13/20244.56 undefined
8/12/20244.38 undefined
8/9/20244.16 undefined
8/8/20244.01 undefined
8/7/20246.11 undefined
8/6/20246.53 undefined
8/5/20246.49 undefined
8/2/20246.71 undefined
8/1/20246.88 undefined
7/31/20247.10 undefined

Cabaletta Bio Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Cabaletta Bio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cabaletta Bio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cabaletta Bio’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cabaletta Bio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cabaletta Bio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cabaletta Bio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cabaletta Bio’s growth potential.

Cabaletta Bio Revenue, EBIT and net profit per share

DateCabaletta Bio RevenueCabaletta Bio EBITCabaletta Bio Net Income
2029e520.18 M undefined0 undefined154.14 M undefined
2028e253.51 M undefined-62.63 M undefined51.38 M undefined
2027e71.96 M undefined-147.88 M undefined-46.13 M undefined
2026e2.19 M undefined-159.02 M undefined-121.97 M undefined
2025e0 undefined-129.99 M undefined-118.5 M undefined
2024e0 undefined-117.42 M undefined-111.39 M undefined
20230 undefined-74.66 M undefined-67.68 M undefined
20220 undefined-54.14 M undefined-52.98 M undefined
20210 undefined-46.31 M undefined-46.29 M undefined
20200 undefined-33.83 M undefined-33.34 M undefined
20190 undefined-18.68 M undefined-22.27 M undefined
20180 undefined-6.19 M undefined-12.2 M undefined
20170 undefined-250,000 undefined-250,000 undefined

Cabaletta Bio Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
000000000271253520
----------3,450.00256.34105.53
-------------
0000000000000
0-6-18-33-46-54-74-117-129-159-147-620
----------7,950.00-207.04-24.51-
0-12-22-33-46-52-67-111-118-121-4651154
--83.3350.0039.3913.0428.8565.676.312.54-61.98-210.87201.96
22.5522.5524.0323.1525.7429.3440.95000000
-------------
Details

Keystats

Revenue and Growth

The Cabaletta Bio Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Cabaletta Bio is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
033136.2108.7122.2106.5241.25
0000000
0000000
0000000
014.34.92.32.33.24
034140.5113.6124.5108.8244.49
000.80.91.47.67.45
0000000
0000000
0000000
0000000
00.20.10.30.40.61.71
00.20.91.21.88.29.16
034.2141.4114.8126.3117253.65
043.900000
01.8171.3175.8230.5270.1469.4
-0.3-12.5-33-66.3-112.6-165.6-233.24
00000038.52
0000000
-0.333.2138.3109.5117.9104.5236.2
0.20.60.91.22.32.54.55
00.11.52.435.78.76
0.10.20.71.53.11.32.69
0000000
0000000
0.30.93.15.18.49.515.99
0000000
0000000
0000031.46
0000031.46
0.30.93.15.18.412.517.45
034.1141.4114.6126.3117253.65
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Cabaletta Bio provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Cabaletta Bio's financial health and stability.

Assets

Cabaletta Bio's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Cabaletta Bio must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Cabaletta Bio after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Cabaletta Bio's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
0-12-16-33-46-52-67
000001,0001,000
0000000
00-115-40
0848111623
0000000
0000000
0-4-16-26-34-46-53
0000-1-20
000-76-27-22
000-77-24-21
0000000
0000000
03711904832187
03711904832187
-------
0000000
033103-3420-40111
0-4.66-16.74-27.41-35.28-48.83-54.24
0000000

Cabaletta Bio stock margins

The Cabaletta Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cabaletta Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cabaletta Bio.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cabaletta Bio's sales revenue. A higher gross margin percentage indicates that the Cabaletta Bio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cabaletta Bio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cabaletta Bio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cabaletta Bio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cabaletta Bio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cabaletta Bio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cabaletta Bio Margin History

Cabaletta Bio Gross marginCabaletta Bio Profit marginCabaletta Bio EBIT marginCabaletta Bio Profit margin
2029e0 %0 %29.63 %
2028e0 %-24.7 %20.27 %
2027e0 %-205.5 %-64.1 %
2026e0 %-7,274.29 %-5,579.62 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Cabaletta Bio Stock Sales Revenue, EBIT, Earnings per Share

The Cabaletta Bio earnings per share therefore indicates how much revenue Cabaletta Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Cabaletta Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cabaletta Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cabaletta Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cabaletta Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cabaletta Bio Revenue, EBIT and net profit per share

DateCabaletta Bio Sales per ShareCabaletta Bio EBIT per shareCabaletta Bio Earnings per Share
2029e10.77 undefined0 undefined3.19 undefined
2028e5.25 undefined0 undefined1.06 undefined
2027e1.49 undefined0 undefined-0.96 undefined
2026e0.05 undefined0 undefined-2.53 undefined
2025e0 undefined0 undefined-2.45 undefined
2024e0 undefined0 undefined-2.31 undefined
20230 undefined-1.82 undefined-1.65 undefined
20220 undefined-1.85 undefined-1.81 undefined
20210 undefined-1.8 undefined-1.8 undefined
20200 undefined-1.46 undefined-1.44 undefined
20190 undefined-0.78 undefined-0.93 undefined
20180 undefined-0.27 undefined-0.54 undefined
20170 undefined-0.01 undefined-0.01 undefined

Cabaletta Bio business model

Cabaletta Bio Inc is a biotech company founded in 2017, based in Philadelphia, Pennsylvania. The founders of the company are Michael Milone and Aimee Payne, both renowned experts in immunology. The business model of Cabaletta Bio Inc is to treat rare diseases using T-cell therapies. T-cell therapy is a form of immunotherapy where the patient's own T-cells, which have been taken from their blood, are genetically modified and then reintroduced to the patient. This process is intended to enable the patient's T-cells to recognize and fight specific diseased cells. Cabaletta Bio Inc focuses on developing therapies for rare autoimmune diseases and difficult-to-treat cancers. The company specializes in the development of CAR-T cell therapies (CAR-T stands for Chimeric Antigen Receptor) that enable the patient's T-cells to attack specific tumor or autoimmune cells in the body. Novel CAR-T cell technologies have been developed to allow the T-cells to recognize disease-specific antigens on cell surfaces. This way, the T-cells can selectively target and destroy diseased cells. Cabaletta Bio Inc is working on various areas of T-cell therapy development. The first area involves developing therapies for rare autoimmune diseases such as systemic scleroderma, Juvenile syndrome, or pemphigus vulgaris. The company has initiated clinical trials and collaborates with other research institutions and companies to advance the development of CAR-T cell therapies. Another area of focus for Cabaletta Bio Inc is treating cancers that are difficult to treat and lack therapeutic options, such as leukemia, solid tumors, or sarcomas. Identifying and targeting specific cells for these types of cancers is particularly challenging. Therefore, the company is actively working to develop novel CAR-T cell technologies that enable the T-cells to recognize and combat diseased cells. Currently, Cabaletta Bio Inc does not offer any commercial products as it is still in the phase of clinical research and development. However, the company aims to advance the development of T-cell therapies and make its technology accessible to patients with rare and difficult-to-treat diseases. Overall, Cabaletta Bio Inc has received recognition and support from leading scientists and organizations in recent years. The company has received several awards and accolades for its work, including the New Frontier Award from the National Organization for Rare Disorders (NORD) and the Fast Track Award from the US Food and Drug Administration (FDA). Cabaletta Bio Inc collaborates closely with various research institutions, universities, and companies to improve its technology and develop new therapies. In summary, Cabaletta Bio Inc is an emerging biotech company specializing in the development of T-cell therapies. The company aims to treat rare and difficult-to-treat diseases and make its technology accessible to patients. Although the company currently does not offer commercial products, it has received recognition and support from leading scientists and organizations in recent years and collaborates closely with various research institutions, universities, and companies to improve its technology and develop new therapies. Cabaletta Bio is one of the most popular companies on Eulerpool.com.

Cabaletta Bio SWOT Analysis

Strengths

1. Innovative Technology: Cabaletta Bio Inc is equipped with advanced technology that positions them at the forefront of the industry.

2. Strong Intellectual Property: The company holds a robust portfolio of patents and trademarks, providing a solid foundation for their products and services.

3. Expert Team: Cabaletta Bio Inc boasts a highly skilled and experienced workforce, comprising experts in various relevant fields.

Weaknesses

1. Limited Market Presence: The company currently has a relatively small market share, hindering their ability to compete with larger competitors.

2. Dependency on Funding: Cabaletta Bio Inc heavily relies on external funding sources, which may pose challenges in terms of sustainability and financial stability.

3. Lack of Product Diversification: The company's product lineup is currently focused on a specific niche, potentially exposing them to market volatility.

Opportunities

1. Growing Market Demand: The increasing demand for innovative medical solutions presents an opportunity for Cabaletta Bio Inc to expand their customer base.

2. Collaborative Partnerships: Forming strategic alliances with other industry players can enable the company to access new markets and resources.

3. Global Expansion: Cabaletta Bio Inc can explore international markets to capitalize on emerging opportunities and diversify their revenue streams.

Threats

1. Regulatory Challenges: Stringent regulations imposed on the healthcare industry can create hurdles for the company's product development and commercialization.

2. Intense Competition: Cabaletta Bio Inc faces competition from both established companies and emerging startups, putting pressure on their market position.

3. Technological Advancements: Rapid advancements in technology may render the company's existing solutions obsolete if they fail to keep pace with industry trends.

Cabaletta Bio Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Cabaletta Bio historical P/E ratio, EBIT, and P/S ratio.

Cabaletta Bio shares outstanding

The number of shares was Cabaletta Bio in 2023 — This indicates how many shares 40.946 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Cabaletta Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cabaletta Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cabaletta Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cabaletta Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Cabaletta Bio.

Cabaletta Bio latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.56 -0.56  (-0.21 %)2024 Q2
3/31/2024-0.49 -0.51  (-5.13 %)2024 Q1
12/31/2023-0.4 -0.46  (-14.94 %)2023 Q4
9/30/2023-0.41 -0.37  (10.13 %)2023 Q3
6/30/2023-0.45 -0.37  (18.03 %)2023 Q2
3/31/2023-0.49 -0.45  (8.09 %)2023 Q1
12/31/2022-0.46 -0.52  (-12.85 %)2022 Q4
9/30/2022-0.49 -0.39  (20.62 %)2022 Q3
6/30/2022-0.51 -0.45  (12.6 %)2022 Q2
3/31/2022-0.61 -0.45  (25.97 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the Cabaletta Bio stock

Eulerpool World ESG Rating (EESG©)

26/ 100

🌱 Environment

24

👫 Social

31

🏛️ Governance

22

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cabaletta Bio list of shareholders

%
Name
Stocks
Change
Date
6.89 % Fred Alger Management, LLC3,327,132-932,32312/31/2023
6.77 % Adage Capital Management, L.P.3,266,645012/31/2023
5.53 % BlackRock Institutional Trust Company, N.A.2,671,316504,12112/31/2023
5.37 % State Street Global Advisors (US)2,594,4701,061,62812/31/2023
5.31 % VR Adviser, LLC2,563,952590,69912/31/2023
4.40 % The Vanguard Group, Inc.2,126,124163,82312/31/2023
4.37 % Lynx1 Capital Advisors LLC2,110,4014,40112/31/2023
4.16 % Deerfield Management Company, L.P.2,007,729-332,38912/31/2023
4.15 % Perceptive Advisors LLC2,003,058870,56712/31/2023
4.14 % Bain Capital Life Sciences Investors, LLC2,000,000012/31/2023
1
2
3
4
5
...
10

Cabaletta Bio Executives and Management Board

Dr. Steven Nichtberger61
Cabaletta Bio Chairman of the Board, President, Chief Executive Officer, Co-Founder (since 2017)
Compensation 1.81 M
Mr. Anup Marda45
Cabaletta Bio Chief Financial Officer
Compensation 1.53 M
Dr. Gwendolyn Binder-Scholl48
Cabaletta Bio President - Science and Technology
Compensation 1.05 M
Dr. David Chang60
Cabaletta Bio Chief Medical Officer
Compensation 974,880
Mr. Mark Simon61
Cabaletta Bio Independent Director (since 2018)
Compensation 80,076
1
2
3

Cabaletta Bio Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,740,230,790,740,920,38
1

Most common questions regarding Cabaletta Bio

What values and corporate philosophy does Cabaletta Bio represent?

Cabaletta Bio Inc represents a strong commitment to developing transformative therapies for patients with B cell-mediated autoimmune diseases. The company's core values focus on innovation, scientific excellence, and dedication to improving patient lives. Cabaletta Bio Inc adopts a patient-centric approach, aiming to deliver novel, scalable, and curative Chimeric AutoAntibody Receptor (CAAR) T-cell therapies. The company's corporate philosophy revolves around collaboration, conducting robust research, and harnessing cutting-edge technologies to address unmet medical needs. Cabaletta Bio Inc strives to achieve clinical advancements, build strategic partnerships, and contribute to the overall advancement of precision medicine in the field of autoimmune diseases.

In which countries and regions is Cabaletta Bio primarily present?

Cabaletta Bio Inc is primarily present in the United States.

What significant milestones has the company Cabaletta Bio achieved?

Cabaletta Bio Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in 2018, raising capital to support its innovative cell therapy programs. Additionally, Cabaletta Bio has entered into strategic partnerships, including a collaboration with Medison Pharma, to accelerate the development and commercialization of potential therapies. Moreover, the company has made progress in advancing its lead product candidate, DSG3-CAART, through clinical trials. Cabaletta Bio Inc's dedication to advancing precision engineered cell therapies has positioned it as a promising player in the field of immune-mediated diseases.

What is the history and background of the company Cabaletta Bio?

Cabaletta Bio Inc. is a biopharmaceutical company that focuses on the development of engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company was founded in 2017, with its headquarters in Radnor, Pennsylvania, United States. Cabaletta Bio Inc. aims to harness the power of its proprietary CAR-T cell platform to create transformative therapies that selectively eliminate only the cells responsible for autoimmune diseases, while sparing healthy cells. With a strong emphasis on research and product development, Cabaletta Bio Inc. is dedicated to advancing innovative treatment options for patients suffering from severe autoimmune disorders.

Who are the main competitors of Cabaletta Bio in the market?

The main competitors of Cabaletta Bio Inc in the market include companies such as Passage Bio, Audentes Therapeutics, and Axovant Gene Therapies. These companies are also involved in the development and commercialization of novel gene therapies aimed at treating various diseases.

In which industries is Cabaletta Bio primarily active?

Cabaletta Bio Inc is primarily active in the biotechnology industry.

What is the business model of Cabaletta Bio?

The business model of Cabaletta Bio Inc focuses on the development and commercialization of cell therapy products for the treatment of B cell-mediated autoimmune diseases. As a clinical-stage biotechnology company, Cabaletta Bio Inc aims to utilize its proprietary technology platform, the proprietary Chimeric AutoAntibody Receptor (CAAR) T-cell technology, to engineer T cells that can selectively eliminate autoreactive B cells. By targeting the underlying cause of autoimmune diseases, Cabaletta Bio Inc strives to provide potentially curative therapies for patients suffering from diseases such as mucosal pemphigus vulgaris and mucosal pemphigoid.

What is the P/E ratio of Cabaletta Bio 2024?

The Cabaletta Bio P/E ratio is -2.12.

What is the P/S ratio of Cabaletta Bio 2024?

The Cabaletta Bio P/S ratio is 0.

What is the AlleAktien quality score of Cabaletta Bio?

The AlleAktien quality score for Cabaletta Bio is 2/10.

What is the revenue of Cabaletta Bio 2024?

The revenue cannot currently be calculated for Cabaletta Bio.

How high is the profit of Cabaletta Bio 2024?

The expected Cabaletta Bio profit is -111.39 M USD.

What is the business model of Cabaletta Bio

The company Cabaletta Bio Inc is a biopharmaceutical company that develops personalized therapies for patients with rare hereditary autoimmune diseases. Cabaletta Bio's business model is based on the use of CAR-T cell therapies tailored to the individual needs of each patient. Cabaletta Bio Inc debuted on the Nasdaq stock exchange in 2018 to finance the company's further growth. Through the Initial Public Offering (IPO), Cabaletta Bio raised $74 million and valued the company at approximately $390 million. Cabaletta Bio's research focuses on three main areas. Firstly, the identification of rare hereditary autoimmune diseases and the development of personalized CAR-T cell therapies. Secondly, the discovery of innovative technologies for CAR-T cell manufacturing. And thirdly, collaboration with leading researchers, universities, and hospitals to improve CAR-T cell therapies. Currently, Cabaletta Bio's key products are the AUTO1 CAR-T cell therapies developed for the treatment of patients with cutaneous T-cell lymphopenia (CTCL) and mucous membrane pemphigoid (MMP). AUTO1 is a personalized therapy manufactured from the patient's own T-cells. The CAR-T cells are designed to specifically target the disease-causing cells of the patient. Cabaletta Bio has also developed a platform technology that enhances the effectiveness of CAR-T cell therapy. This platform, called HeLaMo, is based on the use of helper T-cells to amplify the activity of CAR-T cells in the patient's body. HeLaMo also improves the safety and efficiency of treatment. Cabaletta Bio also has an extensive pipeline of therapies in development targeting various autoimmune diseases. These include autoimmune diseases of the skin, eyes, and central nervous system. Cabaletta Bio's business model is based on partnerships with leading institutions and regulatory agencies. The company has partnerships with the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Cabaletta Bio has also formed a strategic partnership with Regeneron Pharmaceuticals to harness the potential of Cabaletta Bio's technology platform in the field of autoimmune diseases of the eye. Cabaletta Bio is a rapidly growing company with a promising portfolio of personalized CAR-T cell therapies. The company is committed to improving the lives of patients with rare autoimmune diseases and revolutionizing the treatment of autoimmune diseases.

What is the Cabaletta Bio dividend?

Cabaletta Bio pays a dividend of 0 USD distributed over payouts per year.

How often does Cabaletta Bio pay dividends?

The dividend cannot currently be calculated for Cabaletta Bio or the company does not pay out a dividend.

What is the Cabaletta Bio ISIN?

The ISIN of Cabaletta Bio is US12674W1099.

What is the Cabaletta Bio WKN?

The WKN of Cabaletta Bio is A2PTTB.

What is the Cabaletta Bio ticker?

The ticker of Cabaletta Bio is CABA.

How much dividend does Cabaletta Bio pay?

Over the past 12 months, Cabaletta Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cabaletta Bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Cabaletta Bio?

The current dividend yield of Cabaletta Bio is .

When does Cabaletta Bio pay dividends?

Cabaletta Bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cabaletta Bio?

Cabaletta Bio paid dividends every year for the past 0 years.

What is the dividend of Cabaletta Bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cabaletta Bio located?

Cabaletta Bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cabaletta Bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cabaletta Bio from 8/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/29/2024.

When did Cabaletta Bio pay the last dividend?

The last dividend was paid out on 8/29/2024.

What was the dividend of Cabaletta Bio in the year 2023?

In the year 2023, Cabaletta Bio distributed 0 USD as dividends.

In which currency does Cabaletta Bio pay out the dividend?

The dividends of Cabaletta Bio are distributed in USD.

All fundamentals about Cabaletta Bio

Our stock analysis for Cabaletta Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cabaletta Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.